Sean Hall

Sean Hall

Company: Iovance Biotherapeutics Inc.

Job title: Director


Next-Gen TIL: Counteracting the Solid Tumor Microenvironment 9:30 am

Targeting immune checkpoint targets using gene editing Developing tethered cytokine approaches to increase TIL persistence post-infusion Enhancing tumor-specific immunity through enrichment and selectionRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.